StockNews.AI
ABCL
StockNews.AI
210 days

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

1. AbCellera will announce 2024 financial results on February 27, 2025. 2. An earnings conference call will occur same day at 2 PM PT. 3. AbCellera develops antibody medicines for various therapeutic areas. 4. Company focuses on first-in-class programs and innovative collaborations.

Earnings
+15.36%Current Return
VS
+0.56%S&P 500
$3.0601/21 04:28 PM EDTEvent Start
$3.5301/22 10:51 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings announcement has potential impact but lacks immediate catalysts. Similar past events generally led to short-lived stock movements.

How important is it?

Earnings announcements can affect investor sentiment and stock volatility, especially in biotechnology.

Why Short Term?

Results may influence stock price temporarily until further developments occur. Earnings often prompt quick market reactions.

Related Companies

ABCL
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

Related News